Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination
First-line nivolumab plus chemotherapy demonstrated limited efficacy in human epidermal growth factor receptor 2-negative DGC with peritoneal dissemination but achieved a comparable OS to patients without peritoneal dissemination, supporting its potential as a first-line treatment.
Authors
- Shota Fukuoka (ORCID: https://orcid.org/0000-0001-9460-4486)
- Akira Ooki (ORCID: https://orcid.org/0000-0001-7618-5775)
- T. Wakatsuki
- S. Udagawa
- Kei Yoshino (ORCID: https://orcid.org/0000-0002-8062-4379)
- Keitaro Shimozaki (ORCID: https://orcid.org/0000-0002-4559-5699)
- Hiroki Osumi (ORCID: https://orcid.org/0000-0002-4742-0446)
- Eiji Shinozaki (ORCID: https://orcid.org/0000-0002-7448-5894)
- Mariko Ogura (ORCID: https://orcid.org/0000-0002-1004-8425)
- Kenji Yamaguchi (ORCID: https://orcid.org/0000-0003-3313-3048)
- Yukari Suzuki (ORCID: https://orcid.org/0000-0002-9625-4616)
- Keisho Chìn (ORCID: https://orcid.org/0000-0002-2015-8185)
- Moritake Tamba
Institutions
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100143
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00